PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > Formulary Search

Search

Reset

BNF Chapter

BNF Paragraph

Please select a BNF Chapter.

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A to Z of Drugs : C

Records returned : 240 (on 17 May 2024 at 09:54:24).

Drug
Indication
Status
Trust Alignment
Links
Restrictions/Comments
C1-Esterase inhibitor
No Information Returned
04.09.01
06.07.01
Cabergoline
Parkinson's disease
Red
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
Not a 1st-line treatment option. On-going toxicity monitoring required
Cabotegravir
No Information Returned
Cabozantinib
No Information Returned
Caffeine
No Information Returned
Caffeine citrate
No Information Returned
Calamine
No Information Returned
Calcipotriol
No Information Returned
Calcitonin (Salmon)
No Information Returned
Calcitriol
No Information Returned
Calcium acetate
No Information Returned
Calcium acetate/magnesium carbonate
No Information Returned
Calcium carbonate
No Information Returned
Calcium carbonate and simeticone
No Information Returned
Calcium chloride
No Information Returned
Calcium folinate
No Information Returned
Calcium gluconate
No Information Returned
Calcium lactate
No Information Returned
Calcium levofolinate
No Information Returned
Calcium phosphate
No Information Returned
Calcium polystyrene sulfonate
No Information Returned
Camellia sinensis extract
No Information Returned
Canagliflozin
No Information Returned
Canagliflozin/metformin
No Information Returned
08.02.04
10.01.03
10.01.04
Canakinumab
Cryopyrin associated periodic syndrome
Red
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NHSE
Important
Specialist centres only
08.02.04
10.01.03
10.01.04
Canakinumab
Juvenile idiopathic arthritis
Red
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NHSE
Important
Specialist centre only
08.02.04
10.01.03
10.01.04
Canakinumab
Hyperuricaemia and Gout
Non Formulary
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NFD1
02.05.05
04.07.04
Candesartan cilexetil
Migraine (prevention)
Green
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Un
Important
Off-label use
Cannabidiol
No Information Returned
04.08.01
10.02.02
Cannabis (medicinal)
Spasticity and muscle spasm
Blue
Formulations :
  • Oromucosal spray
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
CD
Important
For spasticity in MS. Specialist to prescribe for the first 12 weeks and determine response before transfer of care.
04.08.01
10.02.02
Cannabis (medicinal)
Tuberous sclerosis complex
Red
Formulations :
  • Oral solution
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NFD2
CD
NHSE
Important
Specilaist initiation only.
04.08.01
10.02.02
Cannabis (medicinal)
Epilepsy
Red
Formulations :
  • Oral solution
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
CD
Important
Specialist centres only (including ongoing supply)
Cannabis (medicinal)
Pain (Chronic)
Non Formulary
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NFD1
CD
U
Capecitabine
No Information Returned
Capreomycin
No Information Returned
10.03.02
Capsaicin
Osteoarthritis
Green
Formulations :
  • Cream
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
0.025% cream (Zacin brand) is licensed for this indication. (0.075% Axsain cream is NOT licensed for osteoarthritis)
10.03.02
Capsaicin
Pain (Neuropathic)
Green (see narrative)
Formulations :
  • Cream
ASPH
RSCH
SASH
SABP
Primary Care
BNF NICE SPC
NICE
Important
For patients with localised neuropathic pain who cannot tolerate / wish to avoid oral treatments (amitriptyline or duloxetine)
0.075% cream (Axsain brand) is licensed for this indication
10.03.02
Capsaicin
Pain (Neuropathic)
Non Formulary
Formulations :
  • Patches
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NFD1
Important
For patients with localised neuropathic pain who cannot tolerate / wish to avoid oral treatments (amitriptyline or duloxetine)
Capsicum
No Information Returned
Captopril
No Information Returned
Carbachol
No Information Returned
04.07.03
04.08.01
Carbamazepine
Trigeminal neuralgia
Green
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
04.07.03
04.08.01
Carbamazepine
Epilepsy
Blue
Formulations :
  • Modified release tablets
  • Oral suspension
  • Suppositories
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
Ensure that the patient is maintained on a specific manufacturer’s product
Carbaryl
No Information Returned
Carbenoxolone sodium
No Information Returned
Carbenoxolone sodium compound preparations
No Information Returned
07.01.01
Carbetocin
Uterine atony
Red
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Carbidopa
No Information Returned
Carbimazole
No Information Returned
03.07.00
Carbocisteine
Reduction of sputum viscosity
Green (see narrative)
Formulations :
  • Capsules
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Preferred
Do not use in patients with active peptic ulcer disease or risk of GI bleeding.
03.07.00
Carbocisteine
Reduction of sputum viscosity
Green (see narrative)
Formulations :
  • Sachets (oral solution)
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Reserve for patients with swallowing difficulties (aged 15 years and over)
03.07.00
Carbocisteine
Reduction of sputum viscosity
Green (see narrative)
Formulations :
  • Oral solution
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Reserve for use in children below the age of 15 years.
11.08.01
11.08.03
Carbomer
Dry eyes
Green
Formulations :
  • Eye drops
  • Eye gel
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Mild / moderate dry eye. Prescribe by brand (primary care)
1st line: Aacomer 0.2% eye gel or Aacarb Carbomer 0.2% eye gel 2nd line: Clinitas carbomer 0.2% eye gel or Lumecare carbomer 0.2% eye gel
11.08.01
11.08.03
Carbomer
Dry eyes
Green
Formulations :
  • Eye drops (preservative free)
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Mild / moderate dry eye. Prescribe by brand (primary care)
1st line = Evolve Carbomer 980 prefervative free 0.2% eye gel 2nd line = Xailin 0.2% eye gel
11.08.01
11.08.03
Carbomer
Dry eyes
Green (see narrative)
Formulations :
  • Eye drops (unit dose)
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Mild / moderate dry eye. Prescribe by brand (primary care)
Prescribe as Ocu-Lube Carbomer 0.2% Reserved for occasional use where unit dose is required (e.g. to carry in a bag)
Carbomer 940/980
No Information Returned
Carbomer 974P
No Information Returned
Carboplatin
No Information Returned
07.01.01
Carboprost
Uterine atony
Red
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Carglumic acid
No Information Returned
Cariprazine
No Information Returned
Carisoprodol
No Information Returned
11.08.01
Carmellose sodium
Dry eyes
Green
Formulations :
  • Eye drops
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Mild / moderate dry eye. Prescribe by brand (primary care)
1st line = AaqEye carmellose 0.5% 2nd line = Lumecare Advance Carmellose 0.5%
11.08.01
Carmellose sodium
Dry eyes
Green
Formulations :
  • Eye drops (preservative free)
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Mild / moderate dry eye. Prescribe by brand (primary care)
1st line = Eyeaze Carmellose 0.5% PF or VIZcellose 0.5% PF 2nd line = Carmellose 0.5% PF or Ocu-Lube
11.08.01
Carmellose sodium
Dry eyes
Green (see narrative)
Formulations :
  • Eye drops (unit dose)
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Mild / moderate dry eye. Prescribe by brand (primary care)
Prescribe as Lumecare Singles Carmellose. Reserved for occasional use where unit dose is required (e.g. to carry in a bag)
Carmustine
No Information Returned
Carteolol hydrochloride
No Information Returned
Carvedilol
No Information Returned
Caspofungin
No Information Returned
Castor oil
No Information Returned
Catumaxomab
No Information Returned
Cefaclor
No Information Returned
Cefadroxil
No Information Returned
Cefalexin
No Information Returned
Cefamandole
No Information Returned
Cefazolin sodium
No Information Returned
Cefepime
No Information Returned
Cefixime
No Information Returned
Cefotaxime sodium
No Information Returned
Cefoxitin sodium
No Information Returned
Cefpirome sulfate
No Information Returned
Cefpodoxime
No Information Returned
Cefprozil
No Information Returned
Cefradine
No Information Returned
Ceftazidime pentahydrate
No Information Returned
Ceftriaxone sodium
No Information Returned
Cefuroxime axetil
No Information Returned
Cefuroxime sodium
No Information Returned
10.01.01
Celecoxib
Pain & inflammation - musculoskeletal
Green
Formulations :
  • Capsules
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
Preferred
Preferred COX II inhibitor for licensed indications
Celiprolol hydrochloride
No Information Returned
04.08.01
Cenobamate
Epilepsy
Red
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
For initiation by tertiary centres only
Cerivastatin
No Information Returned
10.01.03
Certolizumab pegol
Any paediatric use
Red
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NHSE
Important
Specialist centres only
10.01.03
Certolizumab pegol
Ankylosing spondylitis
Red
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSCH
SASH
SABP
Primary Care
BNF NICE SPC
ICB
BlueTeq
NICE
10.01.03
Certolizumab pegol
Non-radiographic axial spondyloarthritis
Red
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSCH
SASH
SABP
Primary Care
BNF NICE SPC
ICB
BlueTeq
NICE
10.01.03
Certolizumab pegol
Rheumatoid arthritis
Red
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSCH
SASH
SABP
Primary Care
BNF NICE SPC
ICB
BlueTeq
NICE
Important
Severe disease only
10.01.03
Certolizumab pegol
Psoriatic arthritis
Red
Formulations :
  • Subcutaneous injection (sc)
ASPH
RSCH
SASH
SABP
Primary Care
BNF NICE SPC
ICB
BlueTeq
NICE
10.01.03
Certolizumab pegol
Psoriasis
Red
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
10.01.03
Certolizumab pegol
Psoriasis
Red
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
Certoparin sodium sodium
No Information Returned
03.04.01
Cetirizine hydrochloride
Allergic rhinitis
Green
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
Preferred
03.04.01
Cetirizine hydrochloride
Allergic rhinitis
Green (see narrative)
Formulations :
  • Oral solution
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
2nd line option for patients unable to swallow tablets. Loratadine 5mg/5ml sugar free oral solution (from 2 years) is the 1st-line option in this patient group
03.04.01
Cetirizine hydrochloride
Allergic rhinitis
Non Formulary
Formulations :
  • Capsules
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD1
Cetomacrogol
No Information Returned
Cetrimide
No Information Returned
Cetrorelix
No Information Returned
Cetuximab
No Information Returned
Cetylpyridinium chloride
No Information Returned
Charcoal
No Information Returned
01.09.01
Chenodeoxycholic acid
Metabolic disorders
Red
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NHSE
01.09.01
Chenodeoxycholic acid
Biliary cirrhosis
Red
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NHSE
Chlohexidine gluconate (Emollient)
No Information Returned
Chloral hydrate
No Information Returned
Chlorambucil
No Information Returned
Chloramphenicol
No Information Returned
Chlordiazepoxide hydrochloride
No Information Returned
Chlorhex hydrochloride
No Information Returned
Chlorhexidine acetate
No Information Returned
Chlorhexidine gluconate
No Information Returned
Chlormethine hydrochloride
No Information Returned
Chloroprocaine hydrochloride
No Information Returned
Chloroquine phosphate
No Information Returned
Chloroquine phosphate with proguanil hydrochloride
No Information Returned
Chloroquine sulfate
No Information Returned
Chlorothiazide
No Information Returned
Chloroxylenol
No Information Returned
Chlorphenamine maleate
No Information Returned
04.02.01
Chlorpromazine hydrochloride
Intractable hiccup
Blue
Formulations :
  • Oral solution
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
Transfer to primary care only once stabilised and efficacy is established.
Chlorpropamide
No Information Returned
Chlorprothixene
No Information Returned
Chlortalidone
No Information Returned
Cholera
No Information Returned
Cholesterol
No Information Returned
Cholesterol/simvastatin
No Information Returned
Cholic acid
No Information Returned
Choline salicylate
No Information Returned
09.12.00
Chondroitin
Osteoarthritis
Non Formulary
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Choriogonadotropin alfa
No Information Returned
Chorionic gonadotrophin
No Information Returned
Ciclesonide
No Information Returned
01.05.03
08.02.02
10.01.03
11.08.01
13.05.03
Ciclosporin
Dry eyes
Blue
Formulations :
  • Eye drops (unit dose)
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
0.1% ciclosporin (Ikervis)
01.05.03
08.02.02
10.01.03
11.08.01
13.05.03
Ciclosporin
Psoriatic arthritis
Amber
Formulations :
  • Capsules
  • Oral solution
ASPH
RSCH
SASH
SABP
Primary Care
BNF NICE SPC
Un
NICE
Important
Prescribe by brand
01.05.03
08.02.02
10.01.03
11.08.01
13.05.03
Ciclosporin
Rheumatology indications
Amber
Formulations :
  • Capsules
  • Oral solution
ASPH
RSCH
SASH
SABP
Primary Care
BNF NICE SPC
NICE
Important
Prescribe by brand
01.05.03
08.02.02
10.01.03
11.08.01
13.05.03
Ciclosporin
Dermatology indications
Amber
Formulations :
  • Capsules
  • Oral solution
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
Prescribe by brand
01.05.03
08.02.02
10.01.03
11.08.01
13.05.03
Ciclosporin
Neurology indications
Amber
Formulations :
  • Capsules
  • Oral solution
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Un
Important
Prescribe by brand
01.05.03
08.02.02
10.01.03
11.08.01
13.05.03
Ciclosporin
Uveitis
Amber
Formulations :
  • Capsules
  • Oral solution
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Un
Important
Prescribe by brand
01.05.03
08.02.02
10.01.03
11.08.01
13.05.03
Ciclosporin
Renal indications
Amber
Formulations :
  • Capsules
  • Oral solution
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Un
Important
Prescribe by brand
01.05.03
08.02.02
10.01.03
11.08.01
13.05.03
Ciclosporin
Gastroenterology indications
Red
Formulations :
  • Capsules
  • Oral solution
  • Intravenous infusion
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Un
Important
Prescribe by brand
11.08.01
Ciclosporin 0.05% Eye Drops
Dry eyes
Red
Formulations :
  • Eye drops
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
U
Ciclosporin (Eye Anti Inflammatory)
No Information Returned
Cidofovir
No Information Returned
Cilazapril
No Information Returned
Cilostazol
No Information Returned
Cimetidine
No Information Returned
Cinacalcet hydrochloride
No Information Returned
Cinchocaine hydrochloride
No Information Returned
02.06.04
04.06.00
Cinnarizine
Vestibular disorders
Green
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Ciprofibrate
No Information Returned
Ciprofloxacin
No Information Returned
Ciprofloxacin/fluocinolone
No Information Returned
Ciprofloxain/dexameth
No Information Returned
Cisapride
No Information Returned
Cisatracurium
No Information Returned
Cisplatin
No Information Returned
Citalopram hydrobromide
No Information Returned
Citalopram hydrochloride
No Information Returned
Citric acid monohydrate/ipecacuanha
No Information Returned
08.01.03
08.02.04
Cladribine
Multiple sclerosis
Red
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF NICE SPC
NHSE
NICE
Cladribine (Immunomodulating)
No Information Returned
Clarithromycin
No Information Returned
Clemastine fumarate
No Information Returned
07.02.02
Clindamycin
Bacterial vaginosis
Green
Formulations :
  • Vaginal cream
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
Refer to local antimicrobial guidelines. Oral metronidazole is as effective as topical treatment and is more cost-effective.
Clindamycin hydrochloride
No Information Returned
Clindamycin phosphate
No Information Returned
Clindamycin/hydrocortisone
No Information Returned
Clindamycin/tretinoin
No Information Returned
04.08.01
Clobazam
Epilepsy
Blue
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
CD
Clobetasol propionate
No Information Returned
Clobetasone butyrate
No Information Returned
Clofarabine
No Information Returned
Clofazimine
No Information Returned
Clomethiazole
No Information Returned
Clomethiazole edisilate
No Information Returned
Clomifene citrate
No Information Returned
Clomipramine hydrochloride
No Information Returned
04.08.01
04.08.02
Clonazepam
Epilepsy
Blue
Formulations :
  • Oral solution
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
CD
04.08.01
04.08.02
Clonazepam
Parkinson's disease
Blue
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Un
Important
Rapid eye movement disorder
02.05.02
04.07.04
Clonidine hydrochloride
Migraine (prevention)
Non Formulary
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Clopidogrel
No Information Returned
Cloral betaine
No Information Returned
Clorazepate dipotassium
No Information Returned
Clotiapine
No Information Returned
07.02.02
13.10.02
Clotrimazole
Candidiasis
Green
Formulations :
  • Cream
  • Pessaries
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
04.02.01
Clozapine
Parkinson's Disease (psychosis)
Red
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
BNF NICE SPC
SA
NICE
Important
Patient monitoring and registration required
Coal tar
No Information Returned
Coal tar and corticosteroid preparations
No Information Returned
Coal tar bath preparations
No Information Returned
Co-amilofruse (Amiloride hydrochloride/frusemide)
No Information Returned
Co-amilozide (Amiloride hydrochloride/hydrochlorothiazide)
No Information Returned
Co-amoxiclav (Amoxicillin/clavulanic acid)
No Information Returned
04.09.01
Co-beneldopa
Parkinson's disease
Blue
Formulations :
  • Capsules
  • Capsules (slow release)
  • Dispersible tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF NICE SPC
NICE
04.09.01
Co-beneldopa
Parkinson's disease (challenge test)
Non Formulary
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NFD1
Co-beneldopa (Benserazide/levodopa)
No Information Returned
Cobicistat
No Information Returned
Cobimetinib
No Information Returned
Cocaine
No Information Returned
Cocaine (Eye)
No Information Returned
Cocaine hydrochloride
No Information Returned
04.09.01
Co-careldopa
Parkinson's disease
Blue
Formulations :
  • Tablets
  • Tablets (slow release)
ASPH
RSCH
SASH
SABP
Primary Care
BNF NICE SPC
NICE
04.09.01
Co-careldopa
Parkinson's disease
Red
Formulations :
  • Intestinal gel
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NHSE
04.09.01
Co-careldopa
Parkinson's disease (challenge test)
Non Formulary
Formulations :
  • Not Specified
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
NFD1
Co-careldopa (Carbidopa/levodopa)
No Information Returned
04.07.01
Co-codamol
Pain (non-malignant)
Green (see narrative)
Formulations :
  • Effervescent tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
Fixed combinations are less preferable. Low dose (8/500 co-codamol) not recommended. Effervescent formulations reserved for swallowing difficulties - high sodium content and more costly. Secondary Care - for A&E / discharge only.
04.07.01
Co-codamol
Pain (non-malignant)
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
Fixed combinations are less preferable. Low dose (8/500 co-codamol) not recommended. Secondary Care - for A&E / discharge only.
04.07.01
Co-codamol
Pain (non-malignant)
Green (see narrative)
Formulations :
  • Capsules
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
Fixed combinations are less preferable. Low dose (8/500 co-codamol) not recommended. Secondary Care - for A&E / discharge only.
Co-codamol (Codeine phosphate/paracetamol)
No Information Returned
Co-codaprin (Codeine phosphate/aspirin)
No Information Returned
Cocois
No Information Returned
Co-cyprindiol (Cyprote acetate/ethinylestradiol)
No Information Returned
Cod liver oil
No Information Returned
01.06.02
Co-danthramer
Constipation
Green (see narrative)
Formulations :
  • Oral suspension
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
SA
Important
Only for use in end-of-life patients
Co-danthramer (Dantron/poloxamer 188)
No Information Returned
01.06.02
Co-danthrusate
Constipation
Green (see narrative)
Formulations :
  • Oral suspension
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
SA
Important
Only for use in end-of-life patients
Co-danthrusate (Dantron/docusate sodium)
No Information Returned
01.04.02
03.09.01
04.07.02
Codeine phosphate
Pain (non-malignant)
Green
Formulations :
  • Linctus
  • Oral solution
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
01.04.02
03.09.01
04.07.02
Codeine phosphate
Diarrhoea
Green
Formulations :
  • Oral solution
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
01.04.02
03.09.01
04.07.02
Codeine phosphate
Pain (non-malignant)
Red
Formulations :
  • Injection
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
CD
Codeine phosphate compound mixtures
No Information Returned
Co-dergocrine mesilate
No Information Returned
Co-dydramol
No Information Returned
Co-dydramol (Dihydrocodeine/paracetamol)
No Information Returned
Co-fluampicil(Flucloxacillin/ampicillin)
No Information Returned
Co-flumactone (Hydroflumethiazide/spironolactone)
No Information Returned
10.01.04
Colchicine
Hyperuricaemia and Gout
Green
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
Acute gout
09.06.04
Colecalciferol
Vitamin D deficiency and insufficiency
Green
Formulations :
  • Capsules
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
1,000iu tablets 50,000iu capsules
09.06.04
Colecalciferol
Vitamin D deficiency and insufficiency
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
R
Important
4,000iu tablets reserved for patients unable to comply with weekly dosing
09.06.04
Colecalciferol
Vitamin D deficiency and insufficiency
Green (see narrative)
Formulations :
  • Oral solution
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
R
Important
50,000iu/ml oral solution in ampoules - reserved for patients unable to swallow tablets / capsules
09.06.04
Colecalciferol
Vitamin D deficiency and insufficiency
Green (see narrative)
Formulations :
  • Oral drops
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
R
Important
10,000iu/ml oral drops sugar free - reserved for patients unable to swallow tablets / capsules
09.06.04
Colecalciferol
Vitamin D deficiency and insufficiency
Red
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
R
Important
25,000iu tablets
02.12.00
Colesevelam hydrochloride
Post cholecystectomy
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Un
Important
2nd line. Colestyramine sachets (ordinary sachets, with sugar) are the preferred treatment option.
02.12.00
Colesevelam hydrochloride
Bile acid malabsorption
Blue
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Un
Important
2nd line. Colestyramine sachets (ordinary sachets, with sugar) are the preferred treatment option.
Colestilan
No Information Returned
01.09.01
02.12.00
Colestipol hydrochloride
Bile acid malabsorption
Non Formulary
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
DISCONTINUED
01.09.01
13.03.00
Colestyramine
Post cholecystectomy
Green
Formulations :
  • Sachets (powder)
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Un
Important
Preferred
ONLY for those with gastroenterology referral due to undiagnosed diarrhoea post-op. This is the recommended 1st line treatment option (ordinary sachets, with sugar)
01.09.01
13.03.00
Colestyramine
Post cholecystectomy
Green (see narrative)
Formulations :
  • Sachets (SUGAR FREE powder)
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Un
Important
ONLY for those with gastroenterology referral due to undiagnosed diarrhoea post-op AND are diabetic who request a sugar free formulation. The ordinary powder sachets are 1st line.
01.09.01
13.03.00
Colestyramine
Bile acid malabsorption
Blue
Formulations :
  • Sachets (powder)
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
Preferred
These are the recommended 1st line treatment option (ordinary sachets, with sugar)
01.09.01
13.03.00
Colestyramine
Bile acid malabsorption
Blue
Formulations :
  • Sachets (SUGAR FREE powder)
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
Important
3rd line colestyramine (sugar free) – for diabetic patients who request a sugar free formulation. Most costly preparation. The ordinary powder sachets are 1st line.
Colistimeth sodium
No Information Returned
Colistimethate sodium
No Information Returned
Colistin sulfate
No Information Returned
Co-magaldrox (Magnesium/aluminium hydroxide)
No Information Returned
Combined ethinylestradiol 20mcg
No Information Returned
Combined ethinylestradiol 30mcg
No Information Returned
Combined ethinylestradiol 35mcg
No Information Returned
Combined ethinylestradiol 50mcg
No Information Returned
Combined mestranol
No Information Returned
Co-methiamol (Methionine/paracetamol)
No Information Returned
Compound alginates and proprietary indigestion preparations
No Information Returned
Compound antispasmodic preparations
No Information Returned
Compound iron preparations
No Information Returned
Co-phenotrope (Diphenox hydrochloride/atropine sulfate)
No Information Returned
Co-prenozide (Oxprenolol hydrochloride/cyclopenthiazide)
No Information Returned
Co-proxamol (Dextropropoxyphene hydrochloride/paracetamol)
No Information Returned
Corifollitropin alfa
No Information Returned
Coronavirus vaccine
No Information Returned
Corticosteroids
No Information Returned
Corticotropin
No Information Returned
Cortisone acetate
No Information Returned
Co-simalcite (Simeticone/hydrotalcite)
No Information Returned
Co-tenidone (Atenolol/chlortalidone)
No Information Returned
Co-triamterzide(Triamterene/hydrochlorothiazide)
No Information Returned
Co-trimoxazole(Trimethoprim/sulfamethoxazole)
No Information Returned
Co-zidocapt (Hydrochlorothiazide/captopril)
No Information Returned
Crisantaspase
No Information Returned
Crotamiton
No Information Returned
Cyanocobalamin
No Information Returned
04.06.00
Cyclizine hydrochloride
Vestibular disorders
Green
Formulations :
  • Injection
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
04.06.00
Cyclizine hydrochloride
Nausea and vomiting (palliative care)
Green
Formulations :
  • Injection
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
BNF SPC
04.06.00
Cyclizine hydrochloride
Nausea and vomiting (pregnancy)
Green
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
Un
Important
Preferred
1st line treatment option.
Cyclizine lactate
No Information Returned
Cyclopenthiazide
No Information Returned
Cyclopentolate hydrochloride
No Information Returned
Cyclophosphamide
No Information Returned
Cycloserine
No Information Returned
Cyproheptadine hydrochloride
No Information Returned
06.04.02
Cyproterone acetate
Transgender Health - adults
Amber
Formulations :
  • Tablets
ASPH
RSCH
SASH
SABP
Primary Care
Guidelines BNF SPC
Un
Cystine
No Information Returned
Cytarabine
No Information Returned
 

For information about the icons and status values within this site, please refer to the keys below.

Icon/Links Key

NFD1
Non formulary
NFD2
Not assessed for formulary status. Apply to APC / DTC before use.
CD
Controlled drug. Prescribing and/or storage requirements may apply
R
Restrictions apply
SA
Safety Alert
U
Unlicensed - no UK marketing license in place
Un
Off-label use. Not licensed for this indication.
NHSE
Treatment commissioned by NHS England
CDF
CDF
ICB
Treatment commissioned by the ICB
BlueTeq
BlueTeq form to be completed
NICE
NICE

Traffic Light Status Key

Red
Specialist ONLY drugs - treatment initiated and continued by specialist clinicians
Amber
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care under a formal shared care agreement
Green
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing.
Black
Now referred to as "Non Formulary" but some BLACK drugs remain pending review. Not recommended for use in any health setting across Surrey and NW Sussex health economy.
Amber Star
Now referred to as "Blue" but some Amber Star drugs remain pending review. Prescribing initiated and stabliised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green (see narrative)
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing. Please refer to the narrative on the Drug Profile page where additional information may be conveyed as to the place in therapy or restrictions for use that have been locally agreed.
Non Formulary
Not recommended for use in any health setting across Surrey and NW Sussex health economy. (Formerly BLACK traffic light status)
See Below
Please add a description.
N/A
Please add a description.
Blue
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green - Black
Now referred to as "Do not initiate in new patients" but some GREEN/BLACK drugs remain pending review. These drugs are NOT for new initiations (BLACK, (now referred to as Non Formulary)) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required.
See narrative
See narrative - is applied in instances where there may be more than one traffic light status for a drug. This occurs when the traffic light status may differ between specific cohorts of patients e.g. those of childbearing potential and those who are not (in the case of sodium valproate)
Do not initiate in new patients
These drugs are NOT for new initiations (Non Formulary) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required. (Formerly GREEN/BLACK traffic light status)
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More